SOLUBILITIES AND CRYSTALLIZATION BEHAVIOR OF CIMETIDINE POLYMORPHIC FORM-A AND FORM-B

被引:18
作者
SUDO, S
SATO, K
HARANO, Y
机构
[1] Department of Applied Chemistry, Faculty of Engineering, Osaka City University
[2] Dept. of food Sci and Technol, Fac. of Eng. Fukuyama Univ.
关键词
CRYSTALLIZATION; POLYMORPHISM; SOLUBILITY; SELECTIVE CRYSTALLIZATION; NUCLEATION; MIXED SOLVENT; SURFACE ENERGY;
D O I
10.1252/jcej.24.237
中图分类号
TQ [化学工业];
学科分类号
0817 ;
摘要
For the polymorphic forms A and B of the organic compound cimetidine, their solubilities in H2O, 2-propanol (IPA) and H2O-IPA mixture and their crystallization behavior, mainly from IPA, were studied. It became apparent that form A is more soluble than form B in any solvent and that the solubilities of both forms increase in the order H2O, IPA, H2O-IPA mixture. In IPA as a solvent, at high supersaturation ratio (S(A) greater-than-or-equal-to 3.6), form A, which is of thermodynamically metastable form, was preferentially crystallized regardless of the presence or absence (S(A) greater-than-or-equal-to 4.5) and the form of seeds (S(A) greater-than-or-equal-to 3.6). Phase transition from form A to B was not observed. The primary nucleation rate of form A was also measured at S(A) = 4.8 approximately 6.3 by the waiting-time method and surface energy sigma-A was estimated to be 8.1 x 10(-3) J.m-2. At lower supersaturation ratio (S(A) less-than-or-equal-to 2) the form corresponding to that of the seed was crystallized, contrary to results reported in earlier papers that no form B is obtained from IPA solution. The growth rate of form A was also measured at S(A) = 2.2 approximately 1.3, by the light transmittance method, and sigma-A was estimated to be 5.2 x 10(-3) J.m-2.
引用
收藏
页码:237 / 242
页数:6
相关论文
共 16 条
[1]  
Bavin P. M. G., 1976, Patent GB, Patent No. [1 543 238 (A), 1543238]
[2]   DEFINITION AND ANTAGONISM OF HISTAMINE H2-RECEPTORS [J].
BLACK, JW ;
PARSONS, EM ;
DURANT, CJ ;
DUNCAN, WAM ;
GANELLIN, CR .
NATURE, 1972, 236 (5347) :385-&
[3]   CIMETIDINE - NON-THIOUREA H2-RECEPTOR ANTAGONIST [J].
BRIMBLECOMBE, RW ;
DUNCAN, WAM ;
DURANT, GJ ;
EMMETT, JC ;
GANELLIN, CR ;
PARSONS, ME .
JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, 1975, 3 (02) :86-92
[5]  
Harano Y., 1982, IND CRYSTALLIZATION, P137
[6]   THE POLYMORPHISM OF CIMETIDINE [J].
HEGEDUS, B ;
GOROG, S .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1985, 3 (04) :303-313
[8]  
Ostwald W., 1897, Z PHYS CHEM, V22, P289, DOI [DOI 10.1515/ZPCH-1897-2233, 10.1515/zpch-1897-2233]
[9]  
PRODICKOJIC B, 1979, GAZZ CHIM ITAL, V109, P535
[10]  
Sada Eizo, 1975, J CHEM ENG JPN, V8, P191, DOI 10.1252/jcej. 8.191.